Abstract

How does SARS-CoV-2 cause lung microenvironment disturbance and inflammatory storm is still obscure. We here performed the single-cell transcriptome sequencing from lung, blood, and bone marrow of two dead COVID-19 patients and detected the cellular communication among them. Our results demonstrated that SARS-CoV-2 infection increase the frequency of cellular communication between alveolar type I cells (AT1) or alveolar type II cells (AT2) and myeloid cells triggering immune activation and inflammation microenvironment and then induce the disorder of fibroblasts, club, and ciliated cells, which may cause increased pulmonary fibrosis and mucus accumulation. Further study showed that the increase of T cells in the lungs may be mainly recruited by myeloid cells through ligands/receptors (e.g., ANXA1/FPR1, C5AR1/RPS19, and CCL5/CCR1). Interestingly, we also found that certain ligands/receptors (e.g., ANXA1/FPR1, CD74/COPA, CXCLs/CXCRs, ALOX5/ALOX5AP, CCL5/CCR1) are significantly activated and shared among lungs, blood and bone marrow of COVID-19 patients, implying that the dysregulation of ligands/receptors may lead to immune cell’s activation, migration, and the inflammatory storm in different tissues of COVID-19 patients. Collectively, our study revealed a possible mechanism by which the disorder of cell communication caused by SARS-CoV-2 infection results in the lung inflammatory microenvironment and systemic immune responses across tissues in COVID-19 patients.

Details

Title
Novel insight into the underlying dysregulation mechanisms of immune cell-to-cell communication by analyzing multitissue single-cell atlas of two COVID-19 patients
Author
Qin, Shijie 1 ; Yao, Xiaohong 2 ; Li, Weiwei 3 ; Wang, Canbiao 4 ; Xu, Weijun 5 ; Gan, Zhenhua 6 ; Yang, Yang 3 ; Zhong, Aifang 7 ; Wang, Bin 8   VIAFID ORCID Logo  ; He, Zhicheng 2 ; Wu, Jian 3 ; Wu, Qiuyue 3 ; Jiang, Weijun 3 ; Han, Ying 3 ; Wang, Fan 3 ; Wang, Zhihua 9 ; Ke, Yuehua 10 ; Zhao, Jun 3 ; Gao, Junyin 11 ; Qu, Liang 12 ; Jin, Ping 4 ; Guan, Miao 4   VIAFID ORCID Logo  ; Xia, Xinyi 6   VIAFID ORCID Logo  ; Bian, Xiuwu 2   VIAFID ORCID Logo 

 Jinling Hospital, Nanjing University School of Medicine, Institute of Laboratory Medicine, Nanjing, China (GRID:grid.440259.e) (ISNI:0000 0001 0115 7868); Nanjing Normal University, Laboratory for Comparative Genomics and Bioinformatics, College of Life Science, Nanjing, China (GRID:grid.260474.3) (ISNI:0000 0001 0089 5711) 
 Southwest Hospital, Third Military Medical University (Army Medical University), Institute of Pathology, Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, China (GRID:grid.416208.9) (ISNI:0000 0004 1757 2259); Wuhan Huoshenshan Hospital, Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan, China (GRID:grid.416208.9) 
 Jinling Hospital, Nanjing University School of Medicine, Institute of Laboratory Medicine, Nanjing, China (GRID:grid.440259.e) (ISNI:0000 0001 0115 7868) 
 Nanjing Normal University, Laboratory for Comparative Genomics and Bioinformatics, College of Life Science, Nanjing, China (GRID:grid.260474.3) (ISNI:0000 0001 0089 5711) 
 Jinling Hospital, Nanjing University School of Medicine, Institute of Laboratory Medicine, Nanjing, China (GRID:grid.440259.e) (ISNI:0000 0001 0115 7868); Nanjing University School of Medicine, Department of Gastroenterology, Jinling Hospital, Nanjing, China (GRID:grid.41156.37) (ISNI:0000 0001 2314 964X) 
 Jinling Hospital, Nanjing University School of Medicine, Institute of Laboratory Medicine, Nanjing, China (GRID:grid.440259.e) (ISNI:0000 0001 0115 7868); Wuhan Huoshenshan Hospital, Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan, China (GRID:grid.440259.e) 
 Wuhan Huoshenshan Hospital, Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan, China (GRID:grid.440259.e); Medical Technical Support Division, the 904th Hospital, Changzhou, China (GRID:grid.440259.e) 
 Wuhan Huoshenshan Hospital, Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan, China (GRID:grid.440259.e); Daping Hospital, Third Military Medical University (Army Medical University), Department of Gastroenterology, Chongqing, China (GRID:grid.410570.7) (ISNI:0000 0004 1760 6682) 
 Wuhan Huoshenshan Hospital, Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan, China (GRID:grid.440259.e); Department of Laboratory Medicine and Blood Transfusion, the 907th Hospital, Fujian, China (GRID:grid.440259.e) 
10  Wuhan Huoshenshan Hospital, Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan, China (GRID:grid.440259.e); Chinese PLA Center for Disease Control and Prevention, Beijing, China (GRID:grid.488137.1) (ISNI:0000 0001 2267 2324) 
11  Pulmonary and Critical Care Medicine, Yancheng No.1 People’s Hospital, Yancheng, China (GRID:grid.440259.e) 
12  Wuhan Huoshenshan Hospital, Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan, China (GRID:grid.440259.e); 920 Hospital of the Joint Service Support Force of the Chinese People’s Liberation Army, Department of Laboratory Medicine, Kunming, China (GRID:grid.440259.e) 
Pages
286
Publication year
2023
Publication date
Apr 2023
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2804510185
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.